Less than three months after nabbing the first-ever FDA approval to treat vitiligo, Incyte is looking to widen its therapeutic footprint in the pigmentation disease.

Clene Nanomedicine came up short in a phase 2 trial of its only clinical-stage asset in amyotrophic lateral sclerosis (ALS) but is nonetheless laying a path forward for the drug in the disease.

Mesoblast isn’t giving up on its allogeneic cell therapy remestemcel-L. In September 2020, the FDA took the unusual step of going against its independent expert reviewers and knocked back the company’s approval request for its mesenchymal stromal cell therapy in children with steroid-resistant graft-versus-host disease.

Shortly after securing an FDA clearance last month for its simple, self-operated blood sample collection device, Tasso has teamed up with Catapult Health to help propel its device into people’s homes.

A tumultuous stretch for Scandion Oncology apparently has more treacherous terrain ahead. The company announced Friday a critical trial failure just one month after the CEO and chief operating officer announced their departures.

“Junk DNA” is a bit of a controversial term. It was coined in 1972 to describe the 98% of the genome that doesn’t code for proteins, and, while the name stuck, research over the past two decades has shown it’s far from dormant.

As the cell and gene field builds off a quarter of great scientific progress, the industry may be teetering on the brink of transforming medicine as we know it.

GE Healthcare scored an FDA clearance for MRI software that it says can produce better image quality while providing patients a quicker trip inside the scanner.

The makers of the Invisalign system of plastic orthodontic braces are launching an artificial-intelligence-powered program to allow people at home to track their treatment progress and advance to the next stage when they’re ready.

Cancer cells will stop at nothing to grow—right down to deleting sections of their DNA that contain growth suppression genes. In the process, they sometimes delete genes they need to regulate crucial metabolic pathways, requiring them to recruit backup genes, or paralog genes, to make up for the missing functionality.